CAJ | 학술논문

目的评价不同配比头孢呋辛/三唑巴坦(CXM/TB)的体外抗菌活性.方法采用平皿琼脂二倍稀释法测定不同配比CXM/TB对1436株临床分离致病菌的最低抑菌浓度(MIC).结果不同配比CXM/TB(1:1、2:1、3:1、4:1、8:1和16:1)对1436株临床分离菌具有广谱抗菌作用,CXM/TB 1:1、2:1、3:1的抗菌活性相近,稍强于CXM/TB 4:1、8:1、16:1.不同配比CXM/TB对1109株产β-内酰胺酶菌株中的金葡菌、表皮葡萄球菌、大肠埃希菌、肺炎克雷伯菌、醋酸钙不动杆菌、普通变形菌、奇异变形菌、雷氏普罗威登斯菌、摩氏摩根菌、阴沟肠杆菌、产气肠杆菌、异型柠檬酸杆菌和黏质沙雷菌的MIC_(90)值分别为CXM的1/4～1/32,对产ESBLs大肠埃希菌、肺炎克雷伯菌的MIC_(90)值分别为CXM的1/8～1/16,但对产β-内酰胺酶的铜绿假单胞菌、假单胞菌属(除铜绿假单胞菌)的MIC_(90)值与CXM相近;对不产β-内酰胺酶的金葡菌、表皮葡萄球菌、化脓链球菌、肺炎链球菌、流感嗜血菌、副流感嗜血菌的抗菌活性与CXM相近.不同配比CXM/TB对612株产酶耐药临床分离菌中的金葡菌、表皮葡萄球菌、大肠埃希菌、肺炎克雷伯菌、醋酸钙不动杆菌、普通变形菌、奇异变形菌、产气肠杆菌的MIC_(90)分别为CXM的1/8～1/64.不同配比CXM/TB对MRSA、MRSE、粪肠球菌、假单胞菌属的抗菌活性差.结论不同配比CXM/TB均有较强的体外抗菌活性,CXM/TB 1:1、2:1、3:1的抗菌活性相近,稍优于CXM/TB 4:1、8:1、16:1,TB增强了CXM抗产β-内酰胺酶细菌的活性.
목적 평개불동배비두포부신/삼서파탄(CXM/TB)적체외항균활성.방법 채용평명경지이배희석법측정불동배비CXM/TB대1436주림상분리치병균적최저억균농도(MIC).결과 불동배비CXM/TB(1:1、2:1、3:1、4:1、8:1화16:1)대1436주림상분리균구유엄보항균작용,CXM/TB 1:1、2:1、3:1적항균활성상근,초강우CXM/TB 4:1、8:1、16:1.불동배비CXM/TB대1109주산β-내선알매균주중적금포균、표피포도구균、대장애희균、폐염극뢰백균、작산개불동간균、보통변형균、기이변형균、뢰씨보라위등사균、마씨마근균、음구장간균、산기장간균、이형저몽산간균화점질사뢰균적MIC_(90)치분별위CXM적1/4～1/32,대산ESBLs대장애희균、폐염극뢰백균적MIC_(90)치분별위CXM적1/8～1/16,단대산β-내선알매적동록가단포균、가단포균속(제동록가단포균)적MIC_(90)치여CXM상근;대불산β-내선알매적금포균、표피포도구균、화농련구균、폐염련구균、류감기혈균、부류감기혈균적항균활성여CXM상근.불동배비CXM/TB대612주산매내약림상분리균중적금포균、표피포도구균、대장애희균、폐염극뢰백균、작산개불동간균、보통변형균、기이변형균、산기장간균적MIC_(90)분별위CXM적1/8～1/64.불동배비CXM/TB대MRSA、MRSE、분장구균、가단포균속적항균활성차.결론 불동배비CXM/TB균유교강적체외항균활성,CXM/TB 1:1、2:1、3:1적항균활성상근,초우우CXM/TB 4:1、8:1、16:1,TB증강료CXM항산β-내선알매세균적활성.
Objective To evaluate the in vitro antibacterial activities of cefuroxime/tazobactam (CXM/TB) 1:1, 2:1, 3:1, 4:1, 8:1 and 16:1. Methods The minimal inhibitory concentrations (MICs) of CXM/TB against 1436 clinical isolates of bacteria were tested by standard agar dilution method. Results CXM/TB 1:1, 2:1, 3:1, 4:1, 8:1 and 16:1 had broad antibacterial activities against 1436 clinical isolates, and the activities of CXM/TB 1:1, 2:1 and 3:1 were similar but a little stronger than those of CXM/TB 4:1, 8:1 and 16:1. The MIC_(90) values of CXM/TB 1:1, 2:1, 3:1,4:1, 8:1 and 16:1 were 4～32 times lower than those of CXM against β-lactamase-producing S. aureus, S.epidermidis, E. coli, K. pneumoniae, A. calcoacetius, P. vulgaris, P. mirabilis, P. rettgeri, M. morganii, E. cloacae, E. aerogenes, C. diversus and S. marcescens, 8～16 times lower than those of CXM against ESBLs-producing E. coli and K. pneumoniae. The antibacterial activities of CXM/TAZ 1:1, 2:1, 3:1, 4:1, 8:1 and 16:1 were similar to that of CXM against β-lactamase-producing P. aeruginosa and Pseudomonas spp., and against non-β-lactamase-producing S. aureus, S. epidermidis, S. pyogenes, S. pneumoniae, H. influenzae and H. parainfluenzae. The MIC_(90) values of CXM/TB 1:1, 2:1, 3:1, 4:1, 8:1 and 16:1 against both P-lactamase-producing and cefuroxime-resistant S. aureus, S. epidermidis, E. coli, K. pneumoniae, A. calcoacetius, P. vulgaris, P. mirabilis and E. aerogenes were 8 ～64 times lower than those of CXM. CXM/TB 1:1, 2:1, 3:1, 4:1, 8:1 and 16:1 showed poor antibacterial activities against MRSA, MRSE, E.faecalis, P. aeruginosa and Pseudomonas spp. Conclusions CXM/TB 1:1, 2:1, 3:1, 4:1, 8:1 and 16:1 had potent in vitro antibacterial activities, and tazobactam could enhance the antibacterial activity of cefuroxime against β-lactamase-producing and cefuroxime-resistant strains. The activities of CXM/TB 1:1, 2:1 and 3:1 were similar but a little stronger than those of CXM/TB 4:1, 8:1 and 16:1.